1. (1) Permitted medications.

   1. (a) The following quantitative medications and/or metabolites are permissible in test samples up to the stated concentrations in urine:

      Acepromazine - 10 ng/ml

      Albuterol - 1 ng/ml

      Bupivicaine - 5 ng/ml

      Butorphanol - 300 ng/ml

      Carboxydetomidine - 1 ng/ml

      Clenbuterol - 140 pg/ml (in quarter horse and mixed breed races the presence of clenbuterol is prohibited)

      Mepivacaine - 10 ng/ml

      Promazine - 25 ng/ml

      Pyrilamine - 25 ng/ml

   2. (b) The following quantitative medications and/or metabolites are permissible in test samples up to the stated concentrations in serum or plasma:

      Betamethasone - 10 pg/ml

      Butorphanol - 2 ng/ml

      Clenbuterol - 2 pg/ml (in quarter horse and mixed races the presence of clenbuterol is prohibited)

      Cetirizine - 6 ng/ml

      Cimetidine - 400 ng/ml

      Dantrolene - 100 pg/ml

      Detomidine - 1 ng/ml

      Dexamethasone - 5 pg/ml

      Diclofenac - 5 ng/ml

      DMSO - 10 mcg/ml

      Firocoxib - 20 ng/ml

      Glycopryrrolate - 3 pg/ml

      Guaifenesin - 12 ng/ml

      Isoflupredone - 100 pg/ml

      Lidocaine - 20 pg/ml

      Methocarbamol - 1 ng/ml

      Methylprednisolone - 100 pg/ml

      Omeprazole - 10 ng/ml

      Prednisolone - 1 ng/ml

      *Procaine penicillin - 25 ng/ml

      Ranitidine - 40 ng/ml

      Triamcinolone acetonide - 100 pg/ml

      Xylazine - 200 pg/ml

      *	Administration of procaine penicillin to those horses entered must be reported to the commission and may require surveillance up to six hours prior to post time.

   3. (c) Hair samples in pre- or post-race testing for quarter horses and mixed breed races may not be found to contain clenbuterol, ractopamine, zilpaterol, or albuterol in any concentration.
   4. (d) Where a permitted medication has thresholds in both urine and serum or plasma, as set forth in this section, it is not a defense to a violation that the permitted medication does not exceed both thresholds.

2. (2) Androgenic-anabolic steroids.

   1. (a) The following androgenic-anabolic steroids are permissible in test samples up to the stated concentrations after hydrolysis of conjugates in urine:

      Boldenone (Equipoise) - 15 ng/ml urine in male horses other than geldings - 1 ng/ml in urine for geldings, fillies or mares.

      Nandrolone (Durabolin) - 1 ng/ml urine in geldings, fillies, and mares, and for nandrolone metabolite (5a-oestrane-3β,17a-diol) - 45 ng/ml urine in male horses other than geldings.

      Testosterone - Not greater than 20 ng/ml urine in geldings. Not greater than 55 ng/ml urine in fillies and mares (unless in foal). Samples from male horses other than geldings will not be tested for the presence of testosterone.

   2. (b) The following androgenic-anabolic steroids are permissible in test samples up to the stated free (not conjugated), concentration in plasma or serum:

      Boldenone (equipoise) - 25 pg/ml for all horses regardless of sex.

      Nandrolone (durabolin) - 25 pg/ml for fillies and mares and geldings, male horses other than geldings shall be tested for nandrolone in urine.

      Testosterone - 100 pg/ml in fillies, mares, and geldings.

   3. (c) The sex of the horse must be identified to the laboratory on samples submitted for all pre- and post-race testing designated specifically for AAS screening.
   4. (d) If an anabolic steroid is reported as administered to any horse to assist it with recovery from injury or illness, the horse may be placed on the official veterinarian list until such time as a sample is submitted and the levels are reported below the approved thresholds.
   5. (e) All other androgenic-anabolic steroids are prohibited in race horses.

[Statutory Authority: RCW 67.16.020. WSR 19-13-064, § 260-70-630, filed 6/14/19, effective 7/15/19; WSR 19-03-081, § 260-70-630, filed 1/14/19, effective 2/14/19; WSR 18-07-018, § 260-70-630, filed 3/9/18, effective 4/9/18; WSR 17-07-053, § 260-70-630, filed 3/10/17, effective 4/10/17; WSR 15-13-079, § 260-70-630, filed 6/12/15, effective 7/13/15; WSR 14-13-074, § 260-70-630, filed 6/13/14, effective 7/14/14; WSR 13-07-045, § 260-70-630, filed 3/15/13, effective 4/15/13; WSR 12-07-010, § 260-70-630, filed 3/9/12, effective 4/9/12. Statutory Authority: RCW 67.16.020 and 67.16.040. WSR 08-17-051, § 260-70-630, filed 8/14/08, effective 9/14/08; WSR 08-05-091, § 260-70-630, filed 2/15/08, effective 6/1/08; WSR 06-09-009, § 260-70-630, filed 4/10/06, effective 5/11/06; WSR 05-07-067, § 260-70-630, filed 3/11/05, effective 4/11/05. Statutory Authority: RCW 67.16.020. WSR 04-05-095, § 260-70-630, filed 2/18/04, effective 3/20/04; WSR 03-11-019, § 260-70-630, filed 5/12/03, effective 6/12/03. Statutory Authority: RCW 67.16.040. WSR 96-10-001, § 260-70-630, filed 4/17/96, effective 5/18/96.]